Basket | Login | Register

 
 
 
 

Turkey

Reimbursement of anti-dementia drugs

The availability of medicines in general

The majority (about 75 percent) of drug purchases throughout the country are reimbursable through public sector agencies such as the Pension Fund, and the Social Insurance Agency. [1]

The availability of Alzheimer treatments in Europe

All four anti-dementia drugs are available in Turkey and are part of the reimbursement system. Patients must have a medical report showing that they have Alzheimer’s disease. These reports can only be given in clinical centres and by specialists, but once there is such a report other physicians can also prescribe. The Turkish system does not require any specific examinations to be carried out, nor does it impose upper or lower MMSE scores for reimbursement.

Finally, there are no restrictions for the reimbursement of people living alone or in nursing homes.

 

Donepezil

Rivastigmine

Galantamine

Memantine

Reimbursement

Yes

Yes

Yes

Yes

Initial treatment decision

Specialist doctors

Specialist doctors

Specialist doctors

Specialist doctors

Continuing treatment decision

No restrictions

No restrictions

No restrictions

No restrictions

Required examinations

None

None

None

None

MMSE limits

None

None

None

None

People living alone

No restrictions

No restrictions

No restrictions

No restrictions

People in nursing homes

No restrictions

No restrictions

No restrictions

No restrictions

[1] WHO, Pharmaceuticals in Turkey, accessed September 2006: Http://www.who.dk/pharmaceuticals/Topics/Overview/20020414_8

 

 
 

Last Updated: mercredi 15 juillet 2009

 

 
 

Options

  • Send this page to a friend